Rothschild Redburn upgrades Abbott Labs stock rating on device strength

Abbot Laboratories (NYSE:ABT) received an upgraded stock rating from Rothschild Redburn, who changed their stance from Neutral to Buy and increased the price target from $119 to $127. The company's current trading price of $96.69 positions it below both the analyst target and the firm's calculated Fair Value of $107.38, indicating possible undervaluation.

Rothschild Redburn identified Abbott's Medical Devices business as a key growth driver, projecting an organic growth rate of 10.6% for fiscal 2026. The company's cardiovascular and diabetes operations were cited as strong contributors to this growth, with the diabetes technology segment expected to expand by 11.7% in the same period.

The acquisition of Exact Sciences bolstered Abbott's diagnostics division, enhancing its growth potential and profit margins. Despite competition, Rothschild Redburn remains confident in Abbott's ability to maintain Cologuard as the leading standard in colorectal cancer screening. The firm anticipates a mid-term growth trajectory of 6.5% to 8.5% for the company.

Additionally, Abbott's Volt pulsed field ablation and TactiFlex Duo catheters are expected to fuel acceleration in electrophysiology growth. For investors seeking a deeper understanding of Abbott's prospects, the firm recommends consulting the comprehensive Pro Research Report. Rothschild Redburn also believes that management could unlock further upside by addressing the conglomerate structure and divesting non-essential divisions, such as nutrition, which they argue dilute growth and returns.